St. Louis, Mo.-based Sigma-Aldrich Corp., a life science and high technology company, has closed the acquisition of Rockville, Md.-based BioReliance Holdings, Inc., a provider of biopharmaceutical testing services, from Avista Capital Partners for $350 million in cash, subject to closing adjustments.
BioReliance provides biologic, specialized toxicology and animal health testing to pharmaceutical, biopharmaceutical, diagnostics, and other life science customers worldwide.
In addition, BioReliance, which has operations in Glasgow and Stirling, Scotland, and sales offices in Tokyo and Bangalore, enables clients to launch new small molecule drugs worldwide.
“BioReliance’s global biopharmaceutical testing services will enable Sigma-Aldrich to build a specialized services platform that complements our existing products and technology strengths,” said Sigma-Aldrich CEO and president Rakesh Sachdev.
“It will expand our participation in the fast growing biological drug market and will help forge deeper and stronger strategic ties with existing and new customers,” the Indian American added.
BioReliance will become part of SAFC, the custom manufacturing and services business unit of Sigma-Aldrich.